☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
astellas
Astellas Reports MAA Withdrawn for Avacincaptad Pegol (ACP) in the EU
October 28, 2024
Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer
October 21, 2024
Astellas Join Forces with AviadoBio for AVB-101 Gene Therapy Targeting Frontotemporal Dementia and Other Indications
October 9, 2024
Astellas’ Vyloy (Zolbetuximab) Plus Chemotherapy Gains the EC’s Approval for Advanced Gastric and Gastroesophageal Junction Cancer
September 24, 2024
Astellas Reports the US FDA Listing of DIGITIVA to Manage Heart Failure
September 19, 2024
Astellas Begins the P-III Clinical Evaluation of Fezolinetant for Vasomotor Symptoms (VMS) Among Breast Cancer Patients
August 27, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.